New Study Shows Combining Peregrine's Bavituximab With An Apoptosis-Inducing Agent Ca

[News]

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) announced the publication of new data highlighting the tumor-killing potential of its lead phosphatidylserine (PS)-targeting antibody bavituximab in combination with an agent that induces apoptosis, or programmed cell death...

More... (http://mnt.to/f/3Bk5)